Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial Apoptosis

Area of Science:

• Oncology
• Virology
• Molecular Biology

Background:

• Oncolytic virotherapy offers a novel cancer treatment approach but has limitations as a single agent.
• M1 virus demonstrates preclinical promise as an oncolytic virus.
• Combination therapies are being explored to enhance the efficacy of oncolytic viruses.

Purpose of the Study:

• To investigate the synergistic effects of combining the M1 oncolytic virus with Bcl-2 family inhibitors for cancer therapy.
• To identify specific Bcl-2 family inhibitors that enhance M1 virus-mediated oncolysis.
• To elucidate the molecular mechanisms underlying the enhanced antitumor activity of this combination strategy.

Main Methods:

• Screening of ten Bcl-2 family inhibitors to assess their impact on M1 virus oncolysis in cancer cells.
• In vitro assays to evaluate apoptosis induction and cell death.
• In vivo studies using xenograft mouse models and patient-derived tumor tissues to assess therapeutic efficacy.

Main Results:

• Pan-Bcl-2 inhibitors selectively and significantly augmented M1 virus oncolysis in cancer cells at low doses.
• The combination therapy's efficacy is attributed to Bcl-xL inhibition, which synergizes with M1-induced Bak upregulation to promote apoptosis.
• Significant tumor growth inhibition and prolonged survival were observed in preclinical models treated with the M1 virus and pan-Bcl-2 inhibitors combination.

Conclusions:

• The combination of M1 oncolytic virus and pan-Bcl-2 inhibitors represents a promising strategy for enhanced cancer treatment.
• Bcl-xL inhibition is a key mediator in the synergistic antitumor effect observed with M1 virotherapy.
• This combination therapy holds potential therapeutic value and warrants further clinical investigation.